A number of other equities research analysts have also recently commented on the stock. BidaskClub upgraded shares of Epizyme from a sell rating to a hold rating in a research note on Wednesday. Cowen reiterated a buy rating and set a $18.00 price objective on shares of Epizyme in a research report on Thursday, October 31st. HC Wainwright reiterated a buy rating on shares of Epizyme in a research report on Thursday, October 31st. Finally, Zacks Investment Research cut shares of Epizyme from a hold rating to a sell rating and set a $11.00 price objective on the stock. in a research report on Monday, October 21st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $17.50.
Shares of NASDAQ EPZM traded up $0.78 during trading on Thursday, reaching $15.18. 722,400 shares of the company traded hands, compared to its average volume of 811,703. Epizyme has a 52-week low of $5.14 and a 52-week high of $16.59. The stock has a market capitalization of $1.34 billion, a PE ratio of -8.83 and a beta of 2.40. The firm has a 50 day simple moving average of $10.98 and a 200-day simple moving average of $12.39. The company has a quick ratio of 10.90, a current ratio of 10.90 and a debt-to-equity ratio of 0.03.
Institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC bought a new stake in shares of Epizyme during the second quarter valued at approximately $2,511,000. HarbourVest Partners LLC bought a new stake in Epizyme in the second quarter worth $177,000. TD Asset Management Inc. increased its position in Epizyme by 7.0% in the second quarter. TD Asset Management Inc. now owns 21,394 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 1,400 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Epizyme by 20.1% in the second quarter. Charles Schwab Investment Management Inc. now owns 459,308 shares of the biopharmaceutical company’s stock worth $5,765,000 after purchasing an additional 77,012 shares during the last quarter. Finally, Alps Advisors Inc. bought a new stake in Epizyme in the second quarter worth $2,386,000. Hedge funds and other institutional investors own 86.32% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Recommended Story: How to Track your Portfolio in Google Finance
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.